Abstract Search

ey0020.2-7 | Long-Acting Growth Hormone (LAGH) | ESPEYB20

2.7. Weekly somapacitan is effective and well tolerated in children with GH deficiency: The randomized phase 3 REAL4 trial

BS Miller , JC Blair , MH Rasmussen , A Maniatis , RJ Kildemoes , J Mori , M Polak , RB Bang , V Bottcher , S Stagi , R Horikawa

Brief summary: This multicenter, randomized, controlled, phase 3 study compared the effects of long-acting GH (Somapacitan; 0.16 mg/kg/wk) with daily GH (Norditropin; 0.034 mg/kg/d), in GHD children. The trial was conducted over 52 weeks, followed by an ongoing 3-year single-group extension period. Similar efficacy and safety for somapacitan compared to daily GH was demonstrated over 52 weeks of treatment.Long-acting growth hormone (LAGH) formulations ha...

1 shares

ey0018.10-14 | (1) | ESPEYB18

10.14. Targeted pharmacological therapy restores [beta]-cell function for diabetes remission

S Sachs , A Bastidas-Ponce , S Tritschler , M Bakhti , A Bottcher , MA Sanchez-Garrido , M Tarquis-Medina , M Kleinert , K Fischer , S Jall , A Harger , E Bader , S Roscioni , S Ussar , A Feuchtinger , B Yesildag , A Neelakandhan , CB Jensen , M Cornu , B Yang , B Finan , RD Di Marchi , MH Tschop , FJ Theis , SM Hofmann , TD Muller , H Lickert

Nature Metabolism. 2020;2(2):192209. doi: 10.1038/s42255-020-0171-3.This experimental mouse study examined whether or not dedifferentiated β cells could be reversed or targeted by pharmacological intervention for diabetes remission. They identified evidence for β-cell dedifferentiation and dysfunction which could be reversed by single and combined pharmacological approach...

0 shares

ESPE Yearbook of Paediatric Endocrinology

2.7. Weekly somapacitan is effective and well tolerated in children with GH deficiency: The randomized phase 3 REAL4 trial

10.14. Targeted pharmacological therapy restores [beta]-cell function for diabetes remission

BiosciAbstracts